Last €0.63 EUR
Change Today -0.01 / -1.56%
Volume 631.9K
As of 11:35 AM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (ALEHT) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/14 - €1.12
52 Week Low
10/15/14 - €0.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAXONHIT (ALEHT)

Related News

No related news articles were found.

diaxonhit (ALEHT) Related Businessweek News

No Related Businessweek News Found

diaxonhit (ALEHT) Details

Diaxonhit discovers and commercializes specialty diagnostic products in the transplantation, infectious diseases, and cancer diagnosis specialty areas. Its commercialized product includes Tétanos Quick Stick, a proprietary test, which is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products comprise the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product includes AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also involved in the development of companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

89 Employees
Last Reported Date: 09/24/14
Founded in 1997

diaxonhit (ALEHT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (ALEHT) Key Developments

Diaxonhit Announces Good Performance of BJI InoPlex(R) Test for the Diagnosis of Prosthetic Infections

DIAXONHIT announced the good performance of BJI InoPlex(R), the first blood test for the diagnosis of prosthetic joint infections at a symposium held during the 34(th) RICAI meeting in Paris, France. This performance was derived from BJI InoPlex(R) clinical validation study conducted in two French reference centers for prosthetic joint infections. A large cohort of 455 patients was recruited for this study. Prosthetic joint infections, a major public health issue Each year, nearly 3 million implants are placed in Europe and the United States, including more than 220,000 hip and knee replacements in France. About 10 to 20% of all patients undergoing replacements may experience pain or functional impairment, even long after implant surgery. Identifying whether the cause of such dysfunction is infectious or mechanical becomes necessary. If the diagnosis of prosthetic infections in the weeks or first few months following surgery is usually not a problem because clinical signs are visible, it becomes more difficult with time, thus delaying relevant care of the patient. Infections may indeed become serious complications depending on the pathogenicity of the identified bacterium and the duration of the infection. A new test that, together with the standard assessments, allows practitioners to provide earlier and more tailored patient care. Currently, diagnostic tools available to diagnose prosthetic infections have limited performances, resulting sometimes in unsuitable patient care and late diagnosis. BJI InoPlex(R) is the first test able to detect, directly in the patient's blood, antibodies against bacteria types frequently responsible for prostetic infections, including staphylococci that are the most often encountered bacteria in such infections. With this test, the result of which is made available in a few hours, whereas conventional bacteriological culture requires from several days to over a week, the practitioner receives quick qualitative information by targeted types of bacteria, which enables him, in association with conventional assessments, to accelerate initiation of relevant patient care, particularly in terms of antibiotic therapy. BJI InoPlex(R) only requires a single patient blood sample. After proper preparation, the test is carried out directly in the biology laboratory of the hospital with a standard Luminex instrument. It provides a quick result to the prescriber who is then able to offer a more personalized support to the patient.

DIAXONHIT Starts Cithy Clinical Study for Dx15 Molecular Test Validation

DIAXONHIT announced that the clinical study for the validation of Dx15, a molecular test for thyroid cancer, recently started. The goal of Dx15 is to enable surgeons to assess the benign or malignant status of a thyroid nodule when cytological analysis remains indeterminate. DIAXONHIT is the sponsor of this study entitled CITHY (Cytologie Indéterminée de la THYroïde - Indeterminate Thyroid Cytology), which received a favorable opinion from regulatory authorities. As of October 31, 2014, the first patients were already included in France. DIAXONHIT successfully completed the first two phases of development of DX15. During an initial feasibility study, more than 200 biomarkers that showed a statistically significant difference between benign and malignant nodules, were first identified. It was followed by an identification phase in which several very promising transcriptomic signatures were selected, with different molecular profiles than those of US competitors. With the CITHY clinical study, the final stage of development aims at determining DX15 clinical performance on a statistically significant basis. In this context, the CITHY study will recruit approximately 1,000 patients in twenty European clinical centers, all experts in the diagnosis and monitoring of thyroid cancer. This positioning, deliberately expanded at the beginning of the validation study, allows DIAXONHIT to collaborate at onset with a panel of leading experts in Europe. It should also enable a greater number of patients to rapidly benefit from DX15 as soon as validated.

DIAXONHIT's InGen Announces Renewal of Commercial Partnership with One Lambda, Inc. for Diagnostic Tests in Transplantation

DIAXONHIT announced on behalf of its affiliate, InGen, the renewal of the exclusive commercial partnership for the commercialization in France of diagnostic tests for transplantation developed by One Lambda, Inc. The renewal of this exclusive partnership demonstrates the quality of sales team and the confidence of One Lambda in marketing abilities. It enables the Group to strengthen its investment strategy over the long term in all areas of transplantation in order to further develop this critical market. One Lambda develops and distributes several lines of HLA typing tests utilizing both serological and molecular technologies. It manufactures a comprehensive line of antibody detection products that have been designed to monitor transplant patients, both pre- and post-transplant. They are used to detect HLA antibodies that may cause graft rejection. One Lambda also manufactures laboratory instrumentation, and computer software that are used to simplify and automate testing procedures and final test evaluations. With five different product lines, One Lambda allows laboratories to choose a solution that best suits their needs. HLA tests marketed by DIAXONHIT's InGen are used to assess the compatibility between donor and recipient before transplantation, and to follow-up transplanted patients in order to monitor potential rejection and adjust immunosuppressive treatments accordingly. Before transplantation, HLA typing is performed routinely by serology or molecular biology, as well as detection of anti-HLA antibodies synonymous with increased risk of rejection. After transplantation, rejection is monitored with tests that identify anti-HLA antibodies present in patients. All these tests are performed in the HLA laboratories of the French Blood Bank, and in histocompatibility (immunology) laboratories of university hospitals. The field of transplantation covers all activities related to organ and bone marrow transplants. In 2013, 5,123 transplants were performed in France, up 45% since 2000([2]) with rejection remaining the main risk. The rates of acute rejection within a year after transplantation ranging from 5% (kidney) to 50% (lung)(2), the need for reliable diagnostic tests is essential.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALEHT:FP €0.63 EUR -0.01

ALEHT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NEL ASA 1.36 NOK +0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation ALEHT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAXONHIT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at